MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage.
Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs …
AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.
RIO DE JANEIRO — Kyunghyun Cho says he’s a free man once again. He makes that observation, semi-jokingly, while looking over countless rows of poster
The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
GSK is expecting several key late-stage readouts this year and, if they do not succeed, the company could change its team structure, CEO Luke Miels
MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage.
Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs …